Researchers at the University of Alberta, led by Dr. David Wishart, used LMOM to analyze blood samples from a patient over multiple years. They measured 143 endogenous metabolites in serum and a panel of 140 proteins in plasma. After three to four years, they noticed significant changes in the metabolomics and proteomics results, indicating the possibility of pancreatic cancer. Further clinical diagnostic testing confirmed a 2.6 cm lesion in the tail of the patient’s pancreas, which was successfully removed through surgery.
This case report demonstrates the potential of blood LMOM as a non-invasive tool for early detection of pancreatic cancer. The researchers believe that LMOM could improve patient outcomes by enabling earlier intervention and personalized treatment plans. They call for further translational research to explore the use of LMOM in the clinical management of pancreatic cancer.
